2026-04-14T08:38:54Zhttps://recercat.cat/oai/request

oai:recercat.cat:10230/560142026-04-03T00:38:45Zcom_2072_6col_2072_452952

00925njm 22002777a 4500 dc Miret, Carme author Orive, Miren author Sala i Serra, Maria author García-Gutiérrez, Susana author Sarasqueta, Cristina author Legarreta, Maria José author Redondo, Maximino author Rivero, Amado author Castells, Xavier author Quintana, José María author Garin Boronat, Olatz, 1979- author Ferrer Forés, Maria Montserrat author REDISSEC-CaMISS Group author 2023-03-03T07:40:13Z 2023-03-03T07:40:13Z 2023 Purpose: To obtain reference norms of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L, based on a population of Spanish non-metastatic breast cancer patients at diagnosis and 2 years after, according to relevant demographic and clinical characteristics. Methods: Multicentric prospective cohort study including consecutive women aged ≥ 18 years with a diagnosis of incident non-metastatic breast cancer from April 2013 to May 2015. Health-related quality of life (HRQoL) questionnaires were administered between diagnosis and beginning the therapy, and 2 years after. HRQoL differences according to age, comorbidity and stage were tested with ANOVA or Chi Square test and multivariate linear regression models. Results: 1276 patients were included, with a mean age of 58 years. Multivariate models of EORTC QLQ-C30 summary score and EQ-5D-5L index at diagnosis and at 2-year follow-up show the independent association of comorbidity and tumor stage with HRQoL. The standardized multivariate regression coefficient of EORTC QLQ-C30 summary score was lower (poorer HRQoL) for women with stage II and III than for those with stage 0 at diagnosis (- 0.11 and - 0.07, p < 0.05) and follow-up (- 0.15 and - 0.10, p < 0.01). The EQ-5D-5L index indicated poorer HRQoL for women with Charlson comorbidity index ≥ 2 than comorbidity 0 both at diagnosis (- 0.13, p < 0.001) and follow-up (- 0.18, p < 0.001). Therefore, we provided the reference norms at diagnosis and at the 2-year follow-up, stratified by age, comorbidity index, and tumor stage. Conclusion: These HRQoL reference norms can be useful to interpret the scores of women with non-metastatic breast cancer, comparing them with country-specific reference values for this population. The authors would like to acknowledge the support given by the Basque Government (ref IT1598-22) and by the Ministry of Education (ref PID2020-115738GB-100). Finally, the authors also thank Áurea Martín for her support in English editing, proofreading, and preparing this manuscript for submission. Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after